Table 1 Prevalence of resistance associated substitutions (RASs) and treatment outcome polymorphism (TOPs) at baseline and 12 weeks post treatment (12WPT).

From: Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Protein

RAS/TOP

Prevalence at baseline (n)

Prevalence at 12WPT (n)

P-value

Proportion of RAS/TOP at 12WPT not present at baseline (n)

Previously characterised RAS

 NS5B

150V

41% (204/501)

60% (43/72)

8.77 × 10−4

9% (4/43)

 NS5B

159F

0% (1/501)

6% (4/72)

1.47 × 10−5

75% (3/4)

TOPs

 NS2

119A

4% (22/505)

8% (6/72)

9.37 × 10−2

17% (1/6)

 NS2

132V

20% (100/506)

30% (22/72)

1.94 × 10−2

0% (0/21)

 NS3

67V

44% (222/506)

56% (41/73)

2.33 × 10−2

7% (3/41)

  1. The percentage of the population with each RAS or TOP is shown at baseline and 12WPT. These distributions were compared using a one-sided binomial test and the P-value is shown (nominal P-value, not adjusted for multiple comparison). The percentage of patients where the amino acid at baseline has changed to the RAS or TOP in post-treatment sequence is also shown.
Back to article page